Stryker (SYK) Releases Q2 2019 Earnings Guidance

Share on StockTwits

Stryker (NYSE:SYK) issued an update on its second quarter 2019 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $1.90-1.95 for the period, compared to the Thomson Reuters consensus estimate of $1.96. Stryker also updated its FY 2019 guidance to $8.05-8.20 EPS.

SYK stock traded up $4.80 during trading on Tuesday, hitting $186.96. 2,754,379 shares of the stock traded hands, compared to its average volume of 1,434,516. Stryker has a one year low of $144.75 and a one year high of $199.85. The company has a market capitalization of $67.26 billion, a P/E ratio of 25.58, a P/E/G ratio of 2.19 and a beta of 0.88. The company has a quick ratio of 1.41, a current ratio of 2.02 and a debt-to-equity ratio of 0.72.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, January 29th. The medical technology company reported $2.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.15 by $0.03. Stryker had a net margin of 26.12% and a return on equity of 27.60%. The firm had revenue of $3.80 billion during the quarter, compared to the consensus estimate of $3.73 billion. As a group, research analysts expect that Stryker will post 8.13 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 1.11%. The ex-dividend date is Thursday, March 28th. Stryker’s dividend payout ratio is currently 28.45%.

SYK has been the subject of several analyst reports. Credit Suisse Group raised shares of Stryker to an outperform rating in a report on Thursday, January 31st. JPMorgan Chase & Co. boosted their target price on shares of Stryker from $200.00 to $215.00 and gave the stock an overweight rating in a research note on Tuesday, March 19th. ValuEngine downgraded shares of Stryker from a buy rating to a hold rating in a research note on Thursday, April 18th. Barclays set a $203.00 target price on shares of Stryker and gave the stock a buy rating in a research note on Friday, March 8th. Finally, Citigroup dropped their target price on shares of Stryker from $174.00 to $169.00 and set a neutral rating for the company in a research note on Wednesday, January 2nd. Nine research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Stryker presently has an average rating of Buy and a consensus target price of $192.13.

In other news, Chairman Kevin Lobo sold 41,750 shares of Stryker stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $194.11, for a total transaction of $8,104,092.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP M Kathryn Fink sold 180 shares of Stryker stock in a transaction that occurred on Monday, February 4th. The stock was sold at an average price of $176.77, for a total transaction of $31,818.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 130,455 shares of company stock valued at $24,723,292. Insiders own 7.20% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Stryker (SYK) Releases Q2 2019 Earnings Guidance” was first posted by Zolmax and is the property of of Zolmax. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://zolmax.com/investing/stryker-syk-releases-q2-2019-earnings-guidance/3056174.html.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Read More: Why do companies pay special dividends?

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Brighthouse Financial  Given a $36.00 Price Target by Citigroup Analysts
Brighthouse Financial Given a $36.00 Price Target by Citigroup Analysts
Zacks Investment Research Upgrades TowneBank  to “Hold”
Zacks Investment Research Upgrades TowneBank to “Hold”
Biogen’s  Neutral Rating Reiterated at Citigroup
Biogen’s Neutral Rating Reiterated at Citigroup
Euroseas  Receives Buy Rating from Maxim Group
Euroseas Receives Buy Rating from Maxim Group
Tilly’s Inc  Shares Sold by Deutsche Bank AG
Tilly’s Inc Shares Sold by Deutsche Bank AG
Deutsche Bank AG Sells 9,774 Shares of Simulations Plus, Inc.
Deutsche Bank AG Sells 9,774 Shares of Simulations Plus, Inc.


 
© 2006-2019 Zolmax.